- cafead Nov 11, 2020 at 11:22: AM
via Biogen (NASDAQ:BIIB) might be in deep trouble. The biotech's core multiple sclerosis franchise has been hit hard by generic competition this year, and its plan to recoup these lost sales with newer medicines like Vumerity simply isn't working. What's more, Biogen and Ionis Pharmaceuticals' spinal muscular atrophy medicine, Spinraza, has clearly peaked from a sales standpoint. The drug's global sales slipped by a hefty 10% in the third quarter, compared to the same period a year ago.
article source
article source